A new treatment strategy for hypertension can cut the risk of strokes by around 25 percent and coronary events by around
15 percent according to the preliminary results of a major international trial announced at the American College of
Cardiology Late Breaking Clinical Trials II Meeting in Orlando today.
The 'first look' at the data also found that those on the new treatment strategy had a one third less chance of developing
diabetes compared with the older strategy.
The 19,000 patient Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) had been comparing a new treatment strategy for
hypertension, or high blood pressure, against an old one, in order to discover which is better at preventing various
cardiovascular events such as heart attacks and strokes.
In November 2004, the trial was stopped after the Steering Committee of ASCOT accepted the recommendation of its Data Safety
Monitoring Board that the blood pressure arm of the trial should be stopped, due to far better results for those patients on
the new treatment.
The newer treatment strategy using the calcium channel blocker, amlodipine, and the angiotensin converting enzyme inhibitor,
perindopril was compared with the older treatment strategy based on the beta-blocker, atenolol and the thiazide diuretic,
bendroflumethiazide.
ASCOT study co-chairmen Peter Sever from Imperial College London, UK, and Björn Dahlöf, from the Sahlgrenska University
Hospital, Östra, Sweden, comment: "Although these are only preliminary results, we are confident the overall results will
follow the trend we have seen so far. A reduction of 25 percent in strokes and 15 percent in the incidence of coronary events
can make a huge difference to high blood pressure sufferers. Blood pressure is the commonest risk factor contributing to the
global burden of disease, and with a projected 1.5 billion sufferers of hypertension by 2020 it is vital that we develop more
effective treatments."
The complete results of the ASCOT trial will be made available when all data up to and including the last individual patient
visit have been collected and analysed. Investigators and patients will be informed of the final results of ASCOT when these
data become available. The results will be published in the scientific press.
Of over 19,000 patients randomised to the two different blood pressure strategies, approximately 10,000 patients were also
randomised to treatment with either atorvastatin or placebo in the ASCOT Lipid Lowering Arm (ASCOT-LLA). The ASCOT-LLA was
stopped prematurely in October 2002, as a result of substantial benefits associated with statin use in the prevention of
heart attacks and strokes.
The principal sponsor of ASCOT is Pfizer Inc, New York. Support has also been provided by Servier Research Group, Paris and
Leo Laboratories, Copenhagen.
About ASCOT
Launched in 1997, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) is an independent, investigator-led study aiming to
evaluate different treatment strategies to prevent cardiovascular disease in hypertensive patients.
It is being conducted in over 650 general practices or in 32 regional medical centres across the UK, Ireland and the five
Nordic countries, Sweden, Finland, Denmark, Norway and Iceland.
Number of patients on the ASCOT trial by country
Denmark (including Iceland) -- 1,567
Finland -- 2,382
Norway 2,226
Sweden 4,069
UK and Ireland 9,098
TOTAL 19,342
With over 19,000 patients across the UK, Ireland and Scandinavia, ASCOT is the largest European based prospective, randomised
hypertension trial ever to be conducted.
It is jointly coordinated by Imperial College London (International Centre for Circulatory Health, National Heart and Lung
Institute at St Marys Hospital, London) and Scandinavian Coordinating Centre (Scandinavian CRI AB), Göteborg, Sweden.
Reference URL
ascotstudy
Contact:
Tony Stephenson
imperial.ac
at.stephensonimperial.ac
+44 (0) 20 7594 6712
Posted By:
imperial.ac
SOURCE: alphagalileo